CUFinder

Eva Maria Gamper

About Eva Maria Gamper

Eva Maria Gamper, With an exceptional h-index of 28 and a recent h-index of 24 (since 2020), a distinguished researcher at Medizinische Universität Innsbruck, specializes in the field of patient-reported outcome research.

His recent articles reflect a diverse array of research interests and contributions to the field:

Clinical Validity of the Cancer-Specific Utility Measure EORTC QLU-C10D: Retrospective Analyses of Four Lung Cancer Trials Using Six Country Tariffs.

The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands

International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34

Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types

The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for …

The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients

The EORTC QLU-C10D-development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the UK

Synthesis of anchor-based minimally important differences (MID) for the EORTC QLQ-C30 scales across nine cancer sites

Eva Maria Gamper Information

University

Position

Researcher Austria

Citations(all)

2528

Citations(since 2020)

1576

Cited By

1470

hIndex(all)

28

hIndex(since 2020)

24

i10Index(all)

52

i10Index(since 2020)

45

Email

University Profile Page

Google Scholar

Eva Maria Gamper Skills & Research Interests

patient-reported outcome research

Top articles of Eva Maria Gamper

Clinical Validity of the Cancer-Specific Utility Measure EORTC QLU-C10D: Retrospective Analyses of Four Lung Cancer Trials Using Six Country Tariffs.

2024/3/29

Simone Seyringer
Simone Seyringer

H-Index: 2

Richard Norman
Richard Norman

H-Index: 26

Tobias Hell
Tobias Hell

H-Index: 8

The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands

The European Journal of Health Economics

2024/3/14

Richard Norman
Richard Norman

H-Index: 26

Eva Maria Gamper
Eva Maria Gamper

H-Index: 21

International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34

Thyroid

2023/9/1

Ioannis Iakovou
Ioannis Iakovou

H-Index: 13

Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types

European Journal of Cancer

2023/7/1

Mogens Groenvold
Mogens Groenvold

H-Index: 40

Galina Velikova
Galina Velikova

H-Index: 46

Michael Koller
Michael Koller

H-Index: 4

The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for …

European Journal of Cancer

2009/5/1

Galina Velikova
Galina Velikova

H-Index: 46

Colin Johnson
Colin Johnson

H-Index: 5

Dimitrios Kardamakis
Dimitrios Kardamakis

H-Index: 16

Monica Castro
Monica Castro

H-Index: 4

Mark Clemons
Mark Clemons

H-Index: 41

The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients

Endocrine

2023/12/16

Ioannis Iakovou
Ioannis Iakovou

H-Index: 13

Eva Maria Gamper
Eva Maria Gamper

H-Index: 21

The EORTC QLU-C10D-development and investigation of general population utility norms for Canada, France, Germany, Italy, Poland and the UK

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

2022/12/23

Gregor Liegl
Gregor Liegl

H-Index: 11

Richard Norman
Richard Norman

H-Index: 26

Matthias Rose
Matthias Rose

H-Index: 39

Eva Maria Gamper
Eva Maria Gamper

H-Index: 21

Synthesis of anchor-based minimally important differences (MID) for the EORTC QLQ-C30 scales across nine cancer sites

2022/11/25

Mogens Groenvold
Mogens Groenvold

H-Index: 40

Galina Velikova
Galina Velikova

H-Index: 46

Michael Koller
Michael Koller

H-Index: 4

EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals

BMC Public Health

2022/5/24

Gregor Liegl
Gregor Liegl

H-Index: 11

Matthias Rose
Matthias Rose

H-Index: 39

The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights

Journal of patient-reported outcomes

2022/5/4

Richard Norman
Richard Norman

H-Index: 26

Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)

Journal of Neuroendocrinology

2022/4

Barbara King
Barbara King

H-Index: 11

Gregory Kaltsas
Gregory Kaltsas

H-Index: 42

Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials

JNCI: Journal of the National Cancer Institute

2022/3/1

David Cella
David Cella

H-Index: 108

Melanie Calvert
Melanie Calvert

H-Index: 40

Francesco Perrone
Francesco Perrone

H-Index: 1

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

BMC cancer

2021/12

Mogens Groenvold
Mogens Groenvold

H-Index: 40

Galina Velikova
Galina Velikova

H-Index: 46

Estimation of an EORTC QLU-C10 value set for Spain using a discrete choice experiment

Pharmacoeconomics

2021/9

Richard Norman
Richard Norman

H-Index: 26

Rosalie Viney
Rosalie Viney

H-Index: 26

The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L

Journal of Clinical Epidemiology

2021/9/1

Richard Norman
Richard Norman

H-Index: 26

Massimo Breccia
Massimo Breccia

H-Index: 40

Evaluating cost-effectiveness in the management of neuroendocrine neoplasms

2021/9

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D

Quality of Life Research

2021/7

Richard Norman
Richard Norman

H-Index: 26

Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review

2021/4/1

Melanie Calvert
Melanie Calvert

H-Index: 40

Derek Kyte
Derek Kyte

H-Index: 22

David Cella
David Cella

H-Index: 108

French value-set of the QLU-C10D, a cancer-specific utility measure derived from the QLQ-C30

Applied Health Economics and Health Policy

2021/3

Eva Maria Gamper
Eva Maria Gamper

H-Index: 21

Richard Norman
Richard Norman

H-Index: 26

Rosalie Viney
Rosalie Viney

H-Index: 26

Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer

The Journal of Clinical Endocrinology & Metabolism

2020/12

See List of Professors in Eva Maria Gamper University(Medizinische Universität Innsbruck)